{ "source": "Nasdaq Nordic Company News", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "status": "retrieved", "company": "Ascelia Pharma", "reports": [ { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:12:09Z", "company": "Ascelia Pharma AB", "title": "Kvartalsrapport Q1 2026: Orviglance® närmar sig transformerande milstolpar", "category": "Interimsrapport", "date": "2026-05-12", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q1", "period": "2026-q1", "report_key": "2026:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b69e833ef3fd325c14b44bfc91e2a9f2f&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2026-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2026-q1\\release.txt", "attachments": [ { "label": "Ascelia Pharma Q1 2026 SE.pdf", "url": "https://attachment.news.eu.nasdaq.com/afc93eedfdc0d8248fb35c5930da0290d", "final_url": "https://attachment.news.eu.nasdaq.com/afc93eedfdc0d8248fb35c5930da0290d", "filename": "Ascelia_Pharma_Q1_2026_SE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2026-q1\\Ascelia_Pharma_Q1_2026_SE.pdf", "content_type": "application/pdf", "size": 4154819, "sha256": "bc77cf42cc12a08c198dfec56f258a6d51ff4f27c64f8bbb0473f328f0c7adbb", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2026-q1\\Ascelia_Pharma_Q1_2026_SE.pdf", "filename": "Ascelia_Pharma_Q1_2026_SE.pdf", "extension": ".pdf", "size": 4154819, "sha256": "bc77cf42cc12a08c198dfec56f258a6d51ff4f27c64f8bbb0473f328f0c7adbb", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2026-q1\\extracted\\Ascelia_Pharma_Q1_2026_SE\\Ascelia_Pharma_Q1_2026_SE.txt", "text_chars": 46956, "metadata": { "page_count": 22, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2026-q1\\extracted\\Ascelia_Pharma_Q1_2026_SE\\Ascelia_Pharma_Q1_2026_SE.extraction.json" } } ], "announcement_id": "1441450", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:12:21Z", "company": "Ascelia Pharma AB", "title": "Årsredovisning 2025: Orviglance NDA inskickad till FDA, PDUFA datum satt till Juli 2026", "category": "Bokslut och Verksamhetsberättelse", "date": "2026-04-09", "language": "sv", "report_type": "annual-report", "fiscal_year": 2025, "quarter": "annual", "period": "2025-annual", "report_key": "2025:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b09d01f06d38330f139cdb8b92b3580f2&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-annual\\release.txt", "attachments": [ { "label": "Ascelia Pharma Arsredovisning 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a616779d0c144e5181631d424d0a1c6ac", "final_url": "https://attachment.news.eu.nasdaq.com/a616779d0c144e5181631d424d0a1c6ac", "filename": "Ascelia_Pharma_Arsredovisning_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-annual\\Ascelia_Pharma_Arsredovisning_2025.pdf", "content_type": "application/pdf", "size": 15219219, "sha256": "5a1e670cb79ae0cf609fae8beb4c9c0cd92a47ee9f1a4fe17de375ace763b116", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-annual\\Ascelia_Pharma_Arsredovisning_2025.pdf", "filename": "Ascelia_Pharma_Arsredovisning_2025.pdf", "extension": ".pdf", "size": 15219219, "sha256": "5a1e670cb79ae0cf609fae8beb4c9c0cd92a47ee9f1a4fe17de375ace763b116", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-annual\\extracted\\Ascelia_Pharma_Arsredovisning_2025\\Ascelia_Pharma_Arsredovisning_2025.txt", "text_chars": 259489, "metadata": { "page_count": 93, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-annual\\extracted\\Ascelia_Pharma_Arsredovisning_2025\\Ascelia_Pharma_Arsredovisning_2025.extraction.json" } } ], "announcement_id": "1433386", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:12:24Z", "company": "Ascelia Pharma AB", "title": "Bokslutskommuniké och Q4 2025: FDA accepterar Orviglance NDA-ansökan för granskning", "category": "Bokslutskommuniké", "date": "2026-02-05", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2025, "quarter": "q4", "period": "2025-q4", "report_key": "2025:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b8edbdd8cff5d787e93ebd817fa866254&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q4\\release.txt", "attachments": [ { "label": "Ascelia Pharma Q4 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/ac95cf882f063fb0fdbf3803d3a2928d9", "final_url": "https://attachment.news.eu.nasdaq.com/ac95cf882f063fb0fdbf3803d3a2928d9", "filename": "Ascelia_Pharma_Q4_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q4\\Ascelia_Pharma_Q4_2025.pdf", "content_type": "application/pdf", "size": 3748837, "sha256": "95cbd61adaaf2e96b19e143dc511b14d93d090c3f78a9d27f02ac8269d8d427d", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q4\\Ascelia_Pharma_Q4_2025.pdf", "filename": "Ascelia_Pharma_Q4_2025.pdf", "extension": ".pdf", "size": 3748837, "sha256": "95cbd61adaaf2e96b19e143dc511b14d93d090c3f78a9d27f02ac8269d8d427d", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q4\\extracted\\Ascelia_Pharma_Q4_2025\\Ascelia_Pharma_Q4_2025.txt", "text_chars": 52909, "metadata": { "page_count": 23, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q4\\extracted\\Ascelia_Pharma_Q4_2025\\Ascelia_Pharma_Q4_2025.extraction.json" } } ], "announcement_id": "1417953", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:12:30Z", "company": "Ascelia Pharma AB", "title": "Delårsrapport Q3 2025: Orviglance NDA-ansökan inskickad till FDA", "category": "Interimsrapport", "date": "2025-11-05", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q3", "period": "2025-q3", "report_key": "2025:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b4c0ac7b24fd0b3e05b58b7113c01f556&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q3\\release.txt", "attachments": [ { "label": "Ascelia Pharma Q3 2025 SE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a0bd38d3d3473553aaf09a09e9a7bc202", "final_url": "https://attachment.news.eu.nasdaq.com/a0bd38d3d3473553aaf09a09e9a7bc202", "filename": "Ascelia_Pharma_Q3_2025_SE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q3\\Ascelia_Pharma_Q3_2025_SE.pdf", "content_type": "application/pdf", "size": 4443209, "sha256": "e1f87ea0d9d73d455a94bd34665de4a24a52e74000297f0b17796b69270b31f7", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q3\\Ascelia_Pharma_Q3_2025_SE.pdf", "filename": "Ascelia_Pharma_Q3_2025_SE.pdf", "extension": ".pdf", "size": 4443209, "sha256": "e1f87ea0d9d73d455a94bd34665de4a24a52e74000297f0b17796b69270b31f7", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q3\\extracted\\Ascelia_Pharma_Q3_2025_SE\\Ascelia_Pharma_Q3_2025_SE.txt", "text_chars": 51996, "metadata": { "page_count": 23, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q3\\extracted\\Ascelia_Pharma_Q3_2025_SE\\Ascelia_Pharma_Q3_2025_SE.extraction.json" } } ], "announcement_id": "1398696", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:12:35Z", "company": "Ascelia Pharma AB", "title": "Halvårsrapport 2025: Orviglance inlämning av NDA-ansökana närmar sig", "category": "Halvårsrapport", "date": "2025-08-21", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q2", "period": "2025-q2", "report_key": "2025:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b4e2b23a5f5fff25b28ac4cadfe8da712&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q2\\release.txt", "attachments": [ { "label": "Ascelia Pharma Q2 2025 SE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a3d4633d3bd8c209d4e385149d182661e", "final_url": "https://attachment.news.eu.nasdaq.com/a3d4633d3bd8c209d4e385149d182661e", "filename": "Ascelia_Pharma_Q2_2025_SE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q2\\Ascelia_Pharma_Q2_2025_SE.pdf", "content_type": "application/pdf", "size": 4666340, "sha256": "51ee868cb16beb7bcaa6aeed20fdcdc0aac937843ddc0becff6f3b78d319e399", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q2\\Ascelia_Pharma_Q2_2025_SE.pdf", "filename": "Ascelia_Pharma_Q2_2025_SE.pdf", "extension": ".pdf", "size": 4666340, "sha256": "51ee868cb16beb7bcaa6aeed20fdcdc0aac937843ddc0becff6f3b78d319e399", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q2\\extracted\\Ascelia_Pharma_Q2_2025_SE\\Ascelia_Pharma_Q2_2025_SE.txt", "text_chars": 54358, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q2\\extracted\\Ascelia_Pharma_Q2_2025_SE\\Ascelia_Pharma_Q2_2025_SE.extraction.json" } } ], "announcement_id": "1384399", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:12:40Z", "company": "Ascelia Pharma AB", "title": "Kvartalsrapport Q1 2025: Positivt utfall från FDA-möte om Orviglance före NDA-ansökan", "category": "Interimsrapport", "date": "2025-05-16", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q1", "period": "2025-q1", "report_key": "2025:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b9ea9b36d4b231c94af03a4b9d924ff90&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q1\\release.txt", "attachments": [ { "label": "Ascelia Pharma Q1 2025 SE 250516.pdf", "url": "https://attachment.news.eu.nasdaq.com/ab0309755cd233bb89a6ff3debac9b3f2", "final_url": "https://attachment.news.eu.nasdaq.com/ab0309755cd233bb89a6ff3debac9b3f2", "filename": "Ascelia_Pharma_Q1_2025_SE_250516.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q1\\Ascelia_Pharma_Q1_2025_SE_250516.pdf", "content_type": "application/pdf", "size": 4634322, "sha256": "788877cceef954e263a215c074756092b5a865bf4d07f9c35a944cf288d9ed08", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q1\\Ascelia_Pharma_Q1_2025_SE_250516.pdf", "filename": "Ascelia_Pharma_Q1_2025_SE_250516.pdf", "extension": ".pdf", "size": 4634322, "sha256": "788877cceef954e263a215c074756092b5a865bf4d07f9c35a944cf288d9ed08", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q1\\extracted\\Ascelia_Pharma_Q1_2025_SE_250516\\Ascelia_Pharma_Q1_2025_SE_250516.txt", "text_chars": 48845, "metadata": { "page_count": 22, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2025-q1\\extracted\\Ascelia_Pharma_Q1_2025_SE_250516\\Ascelia_Pharma_Q1_2025_SE_250516.extraction.json" } } ], "announcement_id": "1363754", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:12:53Z", "company": "Ascelia Pharma AB", "title": "Årsredovisning 2024: Orviglance går vidare till registreringsfasen efter framgångsrikt slutförande av fas 3-studie", "category": "Bokslut och Verksamhetsberättelse", "date": "2025-04-11", "language": "sv", "report_type": "annual-report", "fiscal_year": 2024, "quarter": "annual", "period": "2024-annual", "report_key": "2024:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b0f00ac372dd574182515b9261b30e206&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-annual\\release.txt", "attachments": [ { "label": "Ascelia Pharma Arsredovisning 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/a00c6afb766258f9d091d3cc61d2ade0e", "final_url": "https://attachment.news.eu.nasdaq.com/a00c6afb766258f9d091d3cc61d2ade0e", "filename": "Ascelia_Pharma_Arsredovisning_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-annual\\Ascelia_Pharma_Arsredovisning_2024.pdf", "content_type": "application/pdf", "size": 16437964, "sha256": "2523d6c1016f772ca129ae42a2ad5fab28b17431c274be29585eabc27293adef", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-annual\\Ascelia_Pharma_Arsredovisning_2024.pdf", "filename": "Ascelia_Pharma_Arsredovisning_2024.pdf", "extension": ".pdf", "size": 16437964, "sha256": "2523d6c1016f772ca129ae42a2ad5fab28b17431c274be29585eabc27293adef", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-annual\\extracted\\Ascelia_Pharma_Arsredovisning_2024\\Ascelia_Pharma_Arsredovisning_2024.txt", "text_chars": 263104, "metadata": { "page_count": 91, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-annual\\extracted\\Ascelia_Pharma_Arsredovisning_2024\\Ascelia_Pharma_Arsredovisning_2024.extraction.json" } } ], "announcement_id": "1355585", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:12:56Z", "company": "Ascelia Pharma AB", "title": "Q4 och Bokslutskommuniké 2024: Slutförande av fullständig studierapport förstärker framgångsrika resultat av SPARKLE fas-3 studien", "category": "Bokslutskommuniké", "date": "2025-02-07", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2024, "quarter": "q4", "period": "2024-q4", "report_key": "2024:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b3632030a6629982bd17878b9cb9d4115&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q4\\release.txt", "attachments": [ { "label": "Ascelia Pharma Q4 2024 SE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a3c8b1c0607ebd46fb8d7adda42ef6d0f", "final_url": "https://attachment.news.eu.nasdaq.com/a3c8b1c0607ebd46fb8d7adda42ef6d0f", "filename": "Ascelia_Pharma_Q4_2024_SE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q4\\Ascelia_Pharma_Q4_2024_SE.pdf", "content_type": "application/pdf", "size": 4221135, "sha256": "fdaa7eaf56e45a1868026ced37edcc3820a1f2e88f14667d1f167bcc54654c69", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q4\\Ascelia_Pharma_Q4_2024_SE.pdf", "filename": "Ascelia_Pharma_Q4_2024_SE.pdf", "extension": ".pdf", "size": 4221135, "sha256": "fdaa7eaf56e45a1868026ced37edcc3820a1f2e88f14667d1f167bcc54654c69", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q4\\extracted\\Ascelia_Pharma_Q4_2024_SE\\Ascelia_Pharma_Q4_2024_SE.txt", "text_chars": 54352, "metadata": { "page_count": 23, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q4\\extracted\\Ascelia_Pharma_Q4_2024_SE\\Ascelia_Pharma_Q4_2024_SE.extraction.json" } } ], "announcement_id": "1341511", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:13:01Z", "company": "Ascelia Pharma AB", "title": "Kvartalsrapport Q3: Framgångsrikt utfall av företrädesemission om 105 MSEK förlänger kassalikviditeten till sent 2025", "category": "Interimsrapport", "date": "2024-11-07", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q3", "period": "2024-q3", "report_key": "2024:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=bc21dfc30d3540aeb444935f06e6972d2&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q3\\release.txt", "attachments": [ { "label": "Ascelia Pharma Q3 2024 SE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a4a60435dc93d1eb08890a823fc155e1f", "final_url": "https://attachment.news.eu.nasdaq.com/a4a60435dc93d1eb08890a823fc155e1f", "filename": "Ascelia_Pharma_Q3_2024_SE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q3\\Ascelia_Pharma_Q3_2024_SE.pdf", "content_type": "application/pdf", "size": 4335024, "sha256": "8051e40d1e7a5358323786a691f7f055eb5418fced2269b42df90f11a851432a", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q3\\Ascelia_Pharma_Q3_2024_SE.pdf", "filename": "Ascelia_Pharma_Q3_2024_SE.pdf", "extension": ".pdf", "size": 4335024, "sha256": "8051e40d1e7a5358323786a691f7f055eb5418fced2269b42df90f11a851432a", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q3\\extracted\\Ascelia_Pharma_Q3_2024_SE\\Ascelia_Pharma_Q3_2024_SE.txt", "text_chars": 54708, "metadata": { "page_count": 23, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q3\\extracted\\Ascelia_Pharma_Q3_2024_SE\\Ascelia_Pharma_Q3_2024_SE.extraction.json" } } ], "announcement_id": "1326321", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:13:15Z", "company": "Ascelia Pharma AB", "title": "Halvårsrapport 2024: Orviglance slutför den kliniska utvecklingen med framgångsrik fas 3-studie", "category": "Halvårsrapport", "date": "2024-08-15", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q2", "period": "2024-q2", "report_key": "2024:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b4956867fb8f131ceadffce5286183d8b&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q2\\release.txt", "attachments": [ { "label": "Ascelia Pharma Q2 2024 SE 240815.pdf", "url": "https://attachment.news.eu.nasdaq.com/a50f6e76c1a4cfe9dcc6f3f7e6bdbe06f", "final_url": "https://attachment.news.eu.nasdaq.com/a50f6e76c1a4cfe9dcc6f3f7e6bdbe06f", "filename": "Ascelia_Pharma_Q2_2024_SE_240815.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q2\\Ascelia_Pharma_Q2_2024_SE_240815.pdf", "content_type": "application/pdf", "size": 4557496, "sha256": "3800d27e1020e4c18138d9c5d2dce7d120b63cdb49e8c8160803a8c825df84dd", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q2\\Ascelia_Pharma_Q2_2024_SE_240815.pdf", "filename": "Ascelia_Pharma_Q2_2024_SE_240815.pdf", "extension": ".pdf", "size": 4557496, "sha256": "3800d27e1020e4c18138d9c5d2dce7d120b63cdb49e8c8160803a8c825df84dd", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q2\\extracted\\Ascelia_Pharma_Q2_2024_SE_240815\\Ascelia_Pharma_Q2_2024_SE_240815.txt", "text_chars": 54245, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q2\\extracted\\Ascelia_Pharma_Q2_2024_SE_240815\\Ascelia_Pharma_Q2_2024_SE_240815.extraction.json" } } ], "announcement_id": "1310856", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:13:18Z", "company": "Ascelia Pharma AB", "title": "Kvartalsrapport Q1: Primärt effektmått uppnått med starka headline-resultat i fas 3-studien med Orviglance", "category": "Interimsrapport", "date": "2024-05-16", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q1", "period": "2024-q1", "report_key": "2024:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=bdf1b0389fdef135169b56502e24911a1&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q1\\release.txt", "attachments": [ { "label": "Ascelia Pharma Q1 2024 SE 240516.pdf", "url": "https://attachment.news.eu.nasdaq.com/a4b3a34203db8ddb9ccdc47c88279ba3f", "final_url": "https://attachment.news.eu.nasdaq.com/a4b3a34203db8ddb9ccdc47c88279ba3f", "filename": "Ascelia_Pharma_Q1_2024_SE_240516.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q1\\Ascelia_Pharma_Q1_2024_SE_240516.pdf", "content_type": "application/pdf", "size": 4494137, "sha256": "34b7f120f5dd9d0b0db38a27f86da644f9b0e04f8602984926e85f239891ff75", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q1\\Ascelia_Pharma_Q1_2024_SE_240516.pdf", "filename": "Ascelia_Pharma_Q1_2024_SE_240516.pdf", "extension": ".pdf", "size": 4494137, "sha256": "34b7f120f5dd9d0b0db38a27f86da644f9b0e04f8602984926e85f239891ff75", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q1\\extracted\\Ascelia_Pharma_Q1_2024_SE_240516\\Ascelia_Pharma_Q1_2024_SE_240516.txt", "text_chars": 46622, "metadata": { "page_count": 22, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2024-q1\\extracted\\Ascelia_Pharma_Q1_2024_SE_240516\\Ascelia_Pharma_Q1_2024_SE_240516.extraction.json" } } ], "announcement_id": "1296034", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:13:31Z", "company": "Ascelia Pharma AB", "title": "Årsredovisning 2023: Solida framsteg med slutförd patientrekrytering till Orviglance fas 3 och förväntat headline-resultat i maj 2024", "category": "Bokslut och Verksamhetsberättelse", "date": "2024-04-08", "language": "sv", "report_type": "annual-report", "fiscal_year": 2023, "quarter": "annual", "period": "2023-annual", "report_key": "2023:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=bda2a301b6d24ae2e9bff4ed8c3672a23&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-annual\\release.txt", "attachments": [ { "label": "Ascelia Pharma Arsredovisning 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a6f550d3eb9eb04ee2ed2f5461835f868", "final_url": "https://attachment.news.eu.nasdaq.com/a6f550d3eb9eb04ee2ed2f5461835f868", "filename": "Ascelia_Pharma_Arsredovisning_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-annual\\Ascelia_Pharma_Arsredovisning_2023.pdf", "content_type": "application/pdf", "size": 16181385, "sha256": "61df62f48fed6af7dad70c02e6d424aa5f716dfc01520f056e23a6fea9714f53", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-annual\\Ascelia_Pharma_Arsredovisning_2023.pdf", "filename": "Ascelia_Pharma_Arsredovisning_2023.pdf", "extension": ".pdf", "size": 16181385, "sha256": "61df62f48fed6af7dad70c02e6d424aa5f716dfc01520f056e23a6fea9714f53", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-annual\\extracted\\Ascelia_Pharma_Arsredovisning_2023\\Ascelia_Pharma_Arsredovisning_2023.txt", "text_chars": 257086, "metadata": { "page_count": 92, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-annual\\extracted\\Ascelia_Pharma_Arsredovisning_2023\\Ascelia_Pharma_Arsredovisning_2023.extraction.json" } } ], "announcement_id": "1286500", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:13:34Z", "company": "Ascelia Pharma AB", "title": "Q4 och bokslutskommuniké 2023: Stärkt finansiell position inför headline-resultat i maj för den kliniska fas-3 studien SPARKLE", "category": "Bokslutskommuniké", "date": "2024-02-09", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2023, "quarter": "q4", "period": "2023-q4", "report_key": "2023:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=bc37e6c44f6bae3b8eee4a241226664ea&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q4\\release.txt", "attachments": [ { "label": "Ascelia Pharma Q4 2023 SE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a83aa3ac4584a5ed5eb687522f6c53272", "final_url": "https://attachment.news.eu.nasdaq.com/a83aa3ac4584a5ed5eb687522f6c53272", "filename": "Ascelia_Pharma_Q4_2023_SE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q4\\Ascelia_Pharma_Q4_2023_SE.pdf", "content_type": "application/pdf", "size": 5600207, "sha256": "7ba68666b6aca63ae4df5542b8ade44ec73c8873506549553a8a48aa897714af", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q4\\Ascelia_Pharma_Q4_2023_SE.pdf", "filename": "Ascelia_Pharma_Q4_2023_SE.pdf", "extension": ".pdf", "size": 5600207, "sha256": "7ba68666b6aca63ae4df5542b8ade44ec73c8873506549553a8a48aa897714af", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q4\\extracted\\Ascelia_Pharma_Q4_2023_SE\\Ascelia_Pharma_Q4_2023_SE.txt", "text_chars": 50975, "metadata": { "page_count": 23, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q4\\extracted\\Ascelia_Pharma_Q4_2023_SE\\Ascelia_Pharma_Q4_2023_SE.extraction.json" } } ], "announcement_id": "1273779", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:13:40Z", "company": "Ascelia Pharma AB", "title": "KVARTALSRAPPORT Q3 2022: Den ny utläsning av bilderna från fas 3-studien SPARKLE fortskrider enligt planen", "category": "Interimsrapport", "date": "2023-11-08", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q3", "period": "2023-q3", "report_key": "2023:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=be1dbee39a2436abecbee0763eee739d4&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q3\\release.txt", "attachments": [ { "label": "Ascelia Pharma Q3 2023 SE 231108.pdf", "url": "https://attachment.news.eu.nasdaq.com/ad8debcc95fb9ebaf2a39f4e11f4cbe83", "final_url": "https://attachment.news.eu.nasdaq.com/ad8debcc95fb9ebaf2a39f4e11f4cbe83", "filename": "Ascelia_Pharma_Q3_2023_SE_231108.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q3\\Ascelia_Pharma_Q3_2023_SE_231108.pdf", "content_type": "application/pdf", "size": 5596085, "sha256": "29876da6ecf825218e5bc5c11982d65e0dd23950c7f76e2dc9b8d217165a6c2f", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q3\\Ascelia_Pharma_Q3_2023_SE_231108.pdf", "filename": "Ascelia_Pharma_Q3_2023_SE_231108.pdf", "extension": ".pdf", "size": 5596085, "sha256": "29876da6ecf825218e5bc5c11982d65e0dd23950c7f76e2dc9b8d217165a6c2f", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q3\\extracted\\Ascelia_Pharma_Q3_2023_SE_231108\\Ascelia_Pharma_Q3_2023_SE_231108.txt", "text_chars": 48935, "metadata": { "page_count": 23, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q3\\extracted\\Ascelia_Pharma_Q3_2023_SE_231108\\Ascelia_Pharma_Q3_2023_SE_231108.extraction.json" } } ], "announcement_id": "1257857", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:13:44Z", "company": "Ascelia Pharma AB", "title": "Halvårsrapport 2023: Ny utläsning krävs efter intraläsarinkonsistens rörande poängsättning av bilder av läsare från fas 3-studien SPARKLE", "category": "Halvårsrapport", "date": "2023-08-18", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q2", "period": "2023-q2", "report_key": "2023:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b699d093efd0878ee0e9cad791c2bca65&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q2\\release.txt", "attachments": [ { "label": "Ascelia Pharma Q2 2023 SE 230817 1 0.pdf", "url": "https://attachment.news.eu.nasdaq.com/a8e47626daae85e5d3f09d934c5a78640", "final_url": "https://attachment.news.eu.nasdaq.com/a8e47626daae85e5d3f09d934c5a78640", "filename": "Ascelia_Pharma_Q2_2023_SE_230817_1_0.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q2\\Ascelia_Pharma_Q2_2023_SE_230817_1_0.pdf", "content_type": "application/pdf", "size": 1362606, "sha256": "596d2844d6a7ea6a7ea215ff21620020f1af3d0b026f448b5ec9c8428fed90dd", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q2\\Ascelia_Pharma_Q2_2023_SE_230817_1_0.pdf", "filename": "Ascelia_Pharma_Q2_2023_SE_230817_1_0.pdf", "extension": ".pdf", "size": 1362606, "sha256": "596d2844d6a7ea6a7ea215ff21620020f1af3d0b026f448b5ec9c8428fed90dd", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q2\\extracted\\Ascelia_Pharma_Q2_2023_SE_230817_1_0\\Ascelia_Pharma_Q2_2023_SE_230817_1_0.txt", "text_chars": 50492, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q2\\extracted\\Ascelia_Pharma_Q2_2023_SE_230817_1_0\\Ascelia_Pharma_Q2_2023_SE_230817_1_0.extraction.json" } } ], "announcement_id": "1243190", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T01:13:49Z", "company": "Ascelia Pharma AB", "title": "KVARTALSRAPPORT Q1 2023: Fas 3 studien för Orviglance, SPARKLE, sista patientens sista besök (Last Patient Last Visit, LPLV) har avslutats", "category": "Interimsrapport", "date": "2023-05-11", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q1", "period": "2023-q1", "report_key": "2023:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b4f9bfcf2b2288a03455413497a756177&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q1\\release.txt", "attachments": [ { "label": "Ascelia Pharma Q1 2023 SE 2023 05 11.pdf", "url": "https://attachment.news.eu.nasdaq.com/a38094033dd5f7565b9bd71081841a20d", "final_url": "https://attachment.news.eu.nasdaq.com/a38094033dd5f7565b9bd71081841a20d", "filename": "Ascelia_Pharma_Q1_2023_SE_2023_05_11.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q1\\Ascelia_Pharma_Q1_2023_SE_2023_05_11.pdf", "content_type": "application/pdf", "size": 1759067, "sha256": "f9ad05d7bcd9de92ec45b89b29b4bb1304970e81881728c5adc66d210f6a6fba", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q1\\Ascelia_Pharma_Q1_2023_SE_2023_05_11.pdf", "filename": "Ascelia_Pharma_Q1_2023_SE_2023_05_11.pdf", "extension": ".pdf", "size": 1759067, "sha256": "f9ad05d7bcd9de92ec45b89b29b4bb1304970e81881728c5adc66d210f6a6fba", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q1\\extracted\\Ascelia_Pharma_Q1_2023_SE_2023_05_11\\Ascelia_Pharma_Q1_2023_SE_2023_05_11.txt", "text_chars": 40790, "metadata": { "page_count": 22, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\nasdaq-reports\\reports\\2023-q1\\extracted\\Ascelia_Pharma_Q1_2023_SE_2023_05_11\\Ascelia_Pharma_Q1_2023_SE_2023_05_11.extraction.json" } } ], "announcement_id": "1227094", "status": "retrieved" } ], "attempts": [ { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Ascelia+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "Ascelia Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "b3707c5c7f72f815d57f84029fd7a6921f235d2722c0ea335645ed46471a255b" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Ascelia+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 100, "pagination": "row-offset", "query_text": "Ascelia Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 98, "new_rows": 98, "total_count": null, "from_cache": false, "body_sha256": "c4feffc7040939788152f032f52cd972d3748e465af37997e297d7b99116b52f" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Ascelia+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=198&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 198, "pagination": "row-offset", "query_text": "Ascelia Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "f7ec81b86060a75e8caa8f070c10e81556aa19553a0414807b9420d737457ae4" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Ascelia+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "Ascelia Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 2, "new_rows": 2, "total_count": null, "from_cache": false, "body_sha256": "a8f5b48d70e04d444fe06f9bcff8055177ec31c26dba00931875afee6a7a6bac" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Ascelia+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=2&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 2, "pagination": "row-offset", "query_text": "Ascelia Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "8cf81a327a3a8b325adfd784ef5b23173c052fd172113cb13a000ad4e443c411" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Ascelia+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "Ascelia Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "1bc402c3b93974add6885dc8d34e2e70d7505470576caa69842371e9211ea719" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Ascelia+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 100, "pagination": "row-offset", "query_text": "Ascelia Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 98, "new_rows": 98, "total_count": null, "from_cache": false, "body_sha256": "fe09d59b2e2df679ce1052bbb10a9eff3b29485db5fba673651dc6b5c0a01763" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Ascelia+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=198&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 198, "pagination": "row-offset", "query_text": "Ascelia Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "f7ec81b86060a75e8caa8f070c10e81556aa19553a0414807b9420d737457ae4" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Ascelia+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "Ascelia Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 1, "new_rows": 1, "total_count": null, "from_cache": false, "body_sha256": "9f748aec7f711687154c271d83280ecab8264ee22e0573774b9a059b682db2f4" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Ascelia+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=1&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 1, "pagination": "row-offset", "query_text": "Ascelia Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "b0baeec2e2e08d034f3e6378faf59c9d544cb3d1cd4e64d2dae5360d27808f71" } ], "identity": { "slug": "", "instrument_id": "TX2983880", "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/ace?id=TX2983880" }, "transport": "ordinary-http", "browser_used": false, "query_text": "Ascelia Pharma", "retrieved_at": "2026-08-07T01:13:49Z" }